Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.

Abstract

OBJECTIVE:

To assess outcomes in patients with lupus nephritis treated with immunosuppressives compared to those treated with cyclophosphamide in a cohort study and in a matched cohort study.

METHODS:

Patients with active renal disease treated with immunosuppressive/cytotoxic medications were selected from the University of Toronto Lupus Clinic database. Five outcomes were evaluated: all-cause mortality, renal failure, reversal of active renal disease, relapse of active renal disease, and toxicity.

RESULTS:

There were no differences in the outcomes of death, renal failure, reversal or relapse of active renal disease, or toxicity in those using or not using cyclophosphamide.

CONCLUSION:

Antimetabolites should be considered standard of care for patients with lupus nephritis both for induction and for maintenance therapy.

• Authors: Murray B Urowitz, Dominique Ibañez, Yaser Ali, Dafna D Gladman
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 34 Issue 7 Pg. 1491-6 (Jul 2007) ISSN: 0315-162X [Print] Canada
• PMID: 17610320 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Immunosuppressive Agents
• Cyclophosphamide
• Mycophenolic Acid
• Azathioprine
• Methotrexate

Topics

• Adult
• Azathioprine (therapeutic use)
• Cohort Studies
• Cyclophosphamide (therapeutic use)
• Drug Therapy, Combination
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Nephritis (drug therapy, mortality, physiopathology)
• Male
• Methotrexate (therapeutic use)
• Mycophenolic Acid (analogs & derivatives, therapeutic use)
• Prognosis
• Severity of Illness Index
• Survival Rate
• Treatment Outcome